Core Viewpoint - Vanda Pharmaceuticals Inc. is facing delays from the FDA regarding the hearing on the approvability of tradipitant for gastroparesis, with the FDA attributing the delay to recent staff reductions, which Vanda disputes as a valid excuse [1][2][3]. Group 1: FDA Delays and Accountability - The FDA has indicated that a reduction in force on April 1 is partially responsible for delaying the recommendation on Vanda's hearing request by at least six months [2]. - Commissioner Dr. Martin Makary has stated that the cuts did not affect scientists or reviewers, raising questions about the validity of the FDA's claims regarding the delay [2][3]. - Vanda argues that the FDA has a history of denying hearing requests for new drug approvability over the past decade, suggesting systemic issues within the agency [3][4]. Group 2: Calls for Change - Vanda urges Commissioner Makary to intervene and restore legal adherence at the FDA, asserting that the culture of delay is not due to targeted reductions in force [5]. - The company emphasizes the need for "radical transparency and common sense" in the FDA's operations, as stated by both Commissioner Makary and Secretary Kennedy [5]. - Vanda's leadership calls for the FDA and DOJ to stop obstructing innovation and to focus on improving decision-making processes [6]. Group 3: Company Overview - Vanda Pharmaceuticals Inc. is a global biopharmaceutical company dedicated to developing innovative therapies to meet significant medical needs and enhance patient lives [7].

Core Insights - Vanda Pharmaceuticals Inc. is participating in the American Academy of Neurology Annual Meeting, presenting a novel therapeutic approach for Charcot-Marie-Tooth disease type 2S (CMT2S) [1][2] - The presentation will showcase VCA-894A, a personalized medicine treatment tailored to a specific genetic mutation, demonstrating significant improvements in neuromuscular function [1][2] - VCA-894A has received orphan designation from the FDA and is expected to be administered to the patient for whom it was developed, highlighting its potential in addressing unmet medical needs [2] Presentation Details - The presentation titled "Translating IGHMBP2 Variants with a CMT2S Patient-specific Organ-on-a-chip Model: Personalized Medicine ASO-based Therapeutic Rescue" will take place on April 9, 2025 [1] - The poster session will include novel unpublished data on conduction velocity in addition to previously published findings [3] Company Overview - Vanda Pharmaceuticals is focused on developing innovative therapies to meet high unmet medical needs and improve patient lives [5]

Core Insights - Vanda Pharmaceuticals Inc. has submitted a New Drug Application (NDA) to the FDA for Bysanti™ (milsaperidone) aimed at treating acute bipolar I disorder and schizophrenia, supported by multiple clinical studies [1][3] - Bysanti™ is classified as an atypical antipsychotic and is believed to work by interacting with various neurotransmitter receptors in the brain [2] - If approved, Bysanti™ could be available in the US by 2026, with potential patent exclusivity extending into the 2040s [3] Company Overview - Vanda Pharmaceuticals is a global biopharmaceutical company focused on developing innovative therapies to meet high unmet medical needs [4]